eClinicalWorks®, the largest ambulatory cloud EHR, today announced that Global Open Wound Care—a mobile wound care clinic specializing in advanced wound treatments and point-of-care treatment decision-making—has selected eClinicalWorks EHR to enhance…
Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today that the Food and Drug Administration…
Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the “Best Emerging…
CAS is the American Chemical Society’s specialized division for scientific information solutions and Molecule.one is the Leading company in biotechnology. The two institutions have entered into a strategic collaboration focused on…
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to three new employees.…
HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with…
Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 33,173,000…
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first…
The United States Direct-To-Consumer Genetic Testing Market is expected to grow at a significant rate to 2028 During the forecast period, rising public awareness of the accessibility of direct-to-consumer genetic…
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce…
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a…